TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients \>/= 18 years of age.~* Patients, who suffer from unresectable and/or metastatic, measurable predominantly clear cell RCC (renal cell carcinoma histologically) or cytologically documented.~* Patients must be previously untreated for advanced disease. Prior palliative radiation therapy is allowed if the target lesion(s) are not included within the radiation field and no more than 30% of the bone marrow is irradiated.~* Patients who have at least one uni-dimensional measurable lesion by computed tomography (CT-scan) or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST).~* Patients with Intermediate or Low risk per the Motzer score.~* Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1.~* Adequate bone marrow, renal and hepatic function as assessed by the following laboratory requirements to be conducted within 7 days prior to study drug treatment~Exclusion Criteria:~* Patients who have received prior systemic treatment regimens for RCC.~* Uncontrolled/unstable cardiac disease~* Uncontrolled hypertension~* Active clinically serious infections (\> Common Terminology Criteria for Adverse Events \[CTCAE\] grade 2 )~* History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.~* Known history or symptomatic metastatic brain or meningeal tumours~* Patients with seizure disorder requiring medication~* Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event \>/= CTCAE Grade 3 within 4 weeks of first dose of study.~* Pregnant or breast-feeding patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regorafenib (Stivarga, BAY73-4506) (Type: EXPERIMENTAL): Participants received Regorafenib 160 mg per os (po) every day (qd) for 3 weeks on 1 week off of every 4 week cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient, male or female subjects of any race, age 12 or older. Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline and practice a reliable method of contraception throughout the study;~* Facial acne vulgaris characterized by the following:~IGA Score \>3 10-50 facial inflammatory lesions (papules,pustules) 10-100 facial non-inflammatory lesions (open/closed comedones)~* Able to understand and comply with the requirements of the study and sign Informed Consent/HIPAA Authorization forms~Exclusion Criteria:~* Female subjects who are pregnant (positive urine pregnancy test), breast feeding, or who are of childbearing potential and not practicing a reliable method of birth control.~* Allergy/sensitivity to any component of the test treatment (Section 5.2), lincomycin, tetracyclines, or sulfites.~* Subjects who have not complied with the proper wash-out periods for prohibited medications/procedures (Supplement 1)\>~* History of clinically significant anemia or hemolysis.~* History of enteritis (regional enteritis, ulcerative colitis, pseudomembranous colitis, or antibiotic-associated colitis).~* Skin disease/disorder that might interfere with the diagnosis or evaluation of acne vulgaris~* Evidence of recent alcohol or drug abuse~* Medical condition that, in the opinion of the Investigator, contraindicates the subject's participation in the clinical study~* History of poor cooperation, non-compliance with medical treatment or unreliability~* Participation in an investigational drug study within 30 days of the baseline visit.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- doxy + aczone (Type: EXPERIMENTAL): Subjects will start treatment with doxycycline 100mg once daily and Aczone 5% gel applied to the face twice daily and those who improve significantly are continued on Aczone gel alone to see if it can maintain therapeutic response

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine In-situ Gel Prior to Intrauterine Device Insertion in Women With no Previous Vaginal Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Non-pregnant women~* Women that did not receive any analgesics or misoprostol in the 24 hours prior to insertion~* Women who delivered only by caesarean section~Exclusion criteria:~* Women with any uterine abnormalities as congenital anomalies, endometrial lesions, adenomyosis, fibroids~* Those with a Category 3 or 4 conditions for intrauterine device insertion according to the WHO Medical Eligibility Criteria for contraceptive use~* Allergy to lidocaine.~* Women refuse to participate in the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- lidocaine group (Type: EXPERIMENTAL): lidocaine in-situ gel inserted vaginally
- placebo group (Type: PLACEBO_COMPARATOR): placebo gel inserted vaginally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Positive skin prick test to Phleum pratense~* Positive IgE to Phleum pratense~* signed informed consent~* A clinical history of moderate to severe persistent rhinoconjunctivitis symptoms~Exclusion Criteria:~* No uncontrolled asthma in the past 12 months~* No history of an IgE mediated systemic reaction due to food, insect venom, any kind of medication or induced by exercise, where there are symptoms both from the skin and the respiratory system with or without hypotension~* No history of an IgE mediated systemic reaction due to food, insect venom, any kind of medication or induced by exercise, where there are symptoms both from the skin and the respiratory system with or without hypotension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Grazax
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of OEF-OIF (Operations Enduring Freedom or Iraqi Freedom) Combat Related PTSD;~2. Female participants of childbearing potential must agree to use an effective method of birth control (i.e., oral contraceptive, Norplant, diaphragm, condom, or spermicide) during the course of the study, or to remain abstinent from sex, to ensure they do not become pregnant during the course of the study;~3. Ability to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments;~4. Participants must be literate in English;~5. Patients must be medically healthy and willing to take the study drug;~6. VRE stimuli available must be consistent with subject's trauma.~Exclusion Criteria:~1. Lifetime or current diagnosis of schizophrenia or other psychotic disorder, bipolar disorder;~2. Participation in a clinical trial during the previous 3 months;~3. Current evidence or history of significant unstable medical illness or organic brain impairment, including stroke, CNS tumor, demyelinating disease, cardiac, pulmonary, gastrointestinal, renal or hepatic impairment;~4. Patients who in the investigator's judgment pose a current suicidal or homicidal risk;~5. Alcohol, medication, or illegal substance dependence within the past 90 days;~6. Treatment with any other concomitant medication with primarily CNS activity, or treatment with any medication that the PI judges not acceptable for this study;~7. history of seizures;~8. Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + Prolonged Imaginal Exposure (Type: PLACEBO_COMPARATOR): Drug: Placebo (sugar pill) + Prolonged Imaginal Exposure (PE) PTSD treatment
- Placebo + VR exposure (Type: PLACEBO_COMPARATOR): Drug: Placebo (sugar pill) + Virtual Reality Exposure (VR) PTSD treatment
- DCS + Prolonged Imaginal Exposure (Type: ACTIVE_COMPARATOR): Drug: 50mg DCS (D-Cycloserine ) + Prolonged Imaginal Exposure (PE) PTSD treatment
- DCS+VR exposure (Type: ACTIVE_COMPARATOR): Drug: 50mg DCS (D-Cycloserine ) + Virtual Reality Exposure (VR) PTSD treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin/Folate Prevention of Large Bowel Polyps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. One neoplastic polyp removed within three months of study entry or within 16 months of study entry if over 1 cm in size or if subject has had a lifetime history of at least two polyps, with the entire large bowel seen by colonoscopy to be free of further polyps within 3 months of entry.~2. An ability and willingness to follow the study protocol, as indicated by the subject's giving informed consent to participate.~3. Good general health, with no severely debilitating diseases or active malignancy that might compromise the patient's ability to complete the study.~4. Anticipated colonoscopic follow-up three years after the qualifying colonoscopy.~5. Age between 21 and 80 years at the time of the intake colonoscopy.~6. For women of childbearing potential, agreement to use effective birth control for the duration of the study.~7. Intent not to take aspirin or aspirin-containing products, NSAIDs or folic acid for the length of the study unless required by a physician.~8. Not randomized previously or currently in a chemoprevention trial, except for the: Nutritional Prevention of Large Bowel Polyps Study (Polyps Prevention Study I); and brief participation in the VA Cooperative Study with no continuing involvement.~Exclusion Criteria:~1. Invasive carcinoma in any colonic polyp removed.~2. Familial colonic polyposis syndromes.~3. Ulcerative colitis or Crohn's disease.~4. Malabsorption syndrome (e.g. pancreatic insufficiency).~5. Large bowel resection for any reason.~6. Diagnosed narcotic or alcohol dependence~7. Contraindication to aspirin use, including:~   1. documented peptic ulcer disease in the past 20 years~  2. aspirin sensitivity~  3. bleeding diathesis, including hemorrhagic stroke~8. Likelihood of NSAID use~   1. recurring arthritis or other musculo-skeletal problems~  2. frequent NSAID use in 5 years preceding~  3. history of stroke or TIAs~  4. history of angina or myocardial infarction~  5. desire to take aspirin for the prevention of cardiovascular disease~9. Required or contraindicated folic acid use pernicious anemia or folic acid deficiency~10. Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be willing and able to provide informed consent.~* Subjects must be willing and able to be confined at the Clinical Research Unit as required by the protocol.~Exclusion Criteria:~* Subjects with any condition affecting drug absorption.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- voriconazole (Type: EXPERIMENTAL): voriconazole twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Intermediate or high grade sarcoma as determined by pathology review~* Musculoskeletal tumor in extremities, trunk or chest wall.~* Primary tumor or isolated locally recurrent tumor greater than 5 cm in diameter.~* Clinical Stage T2N0M0 (AJCC 6th edition)~* Patient is not a candidate for neoadjuvant chemotherapy.~* Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1.~* No steroid therapy within 4 weeks of first dendritic cell administration.~* No coagulation disorder.~* Patient's written informed consent.~* No contraindication to resection.~* Adequate organ function (measured within a week of beginning treatment).~  * White blood count (WBC) \> 3,000/mm to the third power and absolute neutrophil count (ANC) \>1500/mm to the third power~ * Platelets \> 100,000/mm to the third power~ * Hematocrit \> 25%~ * Bilirubin \< 2.0 mg/dL~ * Creatinine \< 2.0 mg/dL, or creatinine clearance \> 60 mL/min~* Radiation Oncologist must confirm that a 2-3 cm strip of skin can be spared from radiation.~Exclusion Criteria:~* Retroperitoneal location.~* Gastrointestinal stromal tumor (GIST).~* Demonstrated metastatic disease.~* Prior radiation therapy if the current tumor is locally recurrent after prior resection.~* Concurrent treatment with any anticancer agent other than radiation as dictated by the protocol.~* Bleeding disorder.~* H.I.V. infection or other primary immunodeficiency disorder.~* Ongoing systemic therapy with immunosuppressant drugs (e.g. corticosteroids, azathioprine, cyclosporin, methotrexate).~* Any serious ongoing infection.~* Pregnant or lactating women -- Patients in reproductive age must agree to use contraceptive methods for the duration of the study (a pregnancy test will be obtained before treatment).~* ECOG performance status of 2, 3 or 4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EBRT + DC Injection + Resection (Type: EXPERIMENTAL): Single Arm: EBRT + DC Injection + Resection. Prior to the fourth DC Injection, participants were assigned to 3 cohorts as outlined in that intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suitable for ECG recording of CBFV and have no adverse reaction to adenosine challenge~* Have a body mass index between 18 and 30 kg/m2~Exclusion Criteria:~* History of clinically significant disease or disorder.~* Abnormal vital signs

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder
- 2 (Type: PLACEBO_COMPARATOR): Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Warfarin Initiation in Mechanical Mitral Valve Replacement Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* New mechanical mitral valve prostheses patients who will receive anticoagulation with warfarin with the use of enoxaparen as a bridging agent.~Exclusion Criteria:~* Pregnant or lactating women~* Renal disorder (GFR = 45\< mL/min) or patients on renal dialysis~* Hepatic disorder (Child Pugh class B or C)~* Clinically significant active bleeding.~* Recurrent DVT or PE.~* Baseline INR \>1.2~* Asian ancestry~* Cancer~* Impaired nutritional status~* Alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): a group of 25 patients received 5mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.~Bleeding events due to overanticoagulation were monitored through the follow up period.
- Group II (Type: EXPERIMENTAL): a group of 25 patients received 3mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.~Bleeding events due to overanticoagulation were monitored through the follow up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female, aged 60 to 64 years.~* Healthy.~Exclusion Criteria:~* Previous vaccination with any licensed or experimental pneumococcal vaccine.~* History of severe adverse reaction associated with a vaccine.~* Immunodeficiency.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Group 1.1 (Type: EXPERIMENTAL): Group 1.1 = 13vPnC then 13vPnC
- Group 1.2 (Type: EXPERIMENTAL): Group 1.2 = 13vPnC then 23vPS
- Group 2 (Type: EXPERIMENTAL): Group 2 = 23vPS then 13vPnC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Drug naive~* Hemoglobin (Hb) A1c \>= 7.0% and \<= 10.0% (\>10% and \<= 12% for open label arm)~* Fasting C-peptide \>= 1 ng/mL~* Body mass index \<= 40 kg/m2~Exclusion Criteria:~* Symptomatic poorly controlled diabetes~* Recent cardiac or cerebrovascular event~* Serum creatinine \>= 1.5 mg/dL for males and \>= 1.4 mg/dL for Women of Child Bearing Potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin 2.5 mg (A) (Type: EXPERIMENTAL): Metformin 500-2000 mg (as needed for rescue)
- Saxagliptin 5 mg (B) (Type: EXPERIMENTAL): Metformin 500-2000 mg (as needed for rescue)
- Saxagliptin 10 mg (C) (Type: EXPERIMENTAL): Metformin 500-2000 mg (as needed for rescue)
- Placebo (D) (Type: PLACEBO_COMPARATOR): Metformin 500-2000 mg (as needed for rescue)
- Open-Label Treatment Cohort (Direct Enrollees) (E) (Type: EXPERIMENTAL): Saxagliptin 10 mg~Metformin 500-2000 mg (as needed for rescue)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients With Severe Preeclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The following parameters of all patients were within the normal range: hematic biometry, urine and glucose tests, aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum creatinine, blood coagulation test including prothrombin time and activated partial thromboplastin time. Electrocardiogram and chest radiography showed no pathological data.~Exclusion Criteria:~When the patient falls outside of the aforementioned parameters, or subjects with unstable medical conditions.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Diltiazem (Type: EXPERIMENTAL): Postpartum patients were administered (60 mg) orally every 8 hours with diltiazem (tables).
- Nifedipine (Type: ACTIVE_COMPARATOR): Postpartum patients were administered (10 mg) orally every 8 hours with nifedipine (capsule).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete